Current Canakinumab Patent Status
Canakinumab (brand name Ilaris), developed by Novartis, holds multiple patents protecting it from biosimilar competition. Key U.S. patents include composition-of-matter protections expiring around 2024-2025, with formulation and method-of-use patents extending to 2030.[1] In Europe, the primary patent expired in 2023, but supplementary protection certificates (SPCs) push exclusivity to 2026 in some countries.[2]
When Do Major Patents Expire?
- U.S.: Core patents (e.g., US 7,829,093 for the monoclonal antibody) expire October 2024. Later patents on manufacturing processes and indications last until 2030-2034.[1][3]
- Europe: Basic patent lapsed in June 2023; SPCs expire 2026 (e.g., in Germany, UK).[2]
- Japan: Exclusivity ends around 2027.[4]
No biosimilars have launched yet due to ongoing patent thickets and litigation risks.
Biosimilar Pipelines and Expected Launches
Several companies are developing canakinumab biosimilars:
- Samsung Bioepis / Biogen: Phase 3 trials completed; U.S. FDA approval filing expected 2024, potential launch post-2025 if patents clear.[5]
- Alvotech / Teva: AVT02 in late-stage development; targeting U.S./EU entry by 2026-2027.[6]
- Intas / Celltrion / Others: Indian and Chinese firms (e.g., Biocon, Innovent) have approvals locally and eye global markets post-2025.[4]
Earliest U.S./EU launches likely 2026-2028, assuming no delays from patent challenges.
Factors Delaying Biosimilar Entry
Patent disputes dominate: Novartis has sued challengers like Samsung over secondary patents, with cases pending in U.S. courts through 2025.[3] FDA biosimilar approval pathway requires 180-day litigation stay, adding 6-12 months post-approval. Manufacturing complexity for this IL-1β inhibitor also slows progress.
How This Compares to Other IL-1 Inhibitors
Unlike anakinra (Kineret), with biosimilars already available since 2022, canakinumab's higher sales ($2B+ annually) draw more scrutiny and defenses.[7] Rilonacept biosimilars trail similarly, eyeing 2027+.
Impact on Pricing and Access
Biosimilars could cut prices 25-40%, based on patterns with Humira/Avastin. Patients with rare autoinflammatory diseases (e.g., CAPS, TRAPS) may see faster access in Europe post-2026.[8]
[1]: DrugPatentWatch.com - Ilaris Patents
[2]: EMA - Ilaris Authorisation
[3]: USPTO Patent Database
[4]: IQVIA Biosimilars Pipeline Report 2024
[5]: Samsung Bioepis Pipeline Update
[6]: Alvotech Q2 2024 Earnings
[7]: Evaluate Pharma World Preview 2024
[8]: GaBI Journal - Biosimilar Savings